ReviewInternational journal of molecular sciences2021
Tumor-Associated Microbiome: Where Do We Stand?
Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 64 citations in OpenAlex.
- Decoding the cancer microbiome: multi-omics, AI, and translational opportunities.Genome biology · 2026Review
- Adaptation of MALDI-TOF MS Technique for Tracking Changes in the Urinary Microbiome During and After Radiotherapy for Prostate Cancer.Cancer management and research · 2026Article
- Intratumoral microbiota remodeling of the tumor microenvironment impact solid tumor immunotherapy.Cell death & disease · 2025Review
- The microbiome of pseudomyxoma peritonei: a scoping review.Pleura and peritoneum · 2025Review
- Microbiome in prostate cancer: pathogenic mechanisms, multi-omics diagnostics, and synergistic therapies.Journal of cancer research and clinical oncology · 2025Review
- Decoding the Tumor-Associated Microbiota: From Origins to Nanomedicine Applications in Cancer Therapy.Biology · 2025Review
- Unlocking the Microbial Symphony: The Interplay of Human Microbiota in Cancer Immunotherapy Response.Cancers · 2025Review
- The cancer microbiome.Advances in clinical chemistry · 2025Review
- IntratumoralPathogens (Basel, Switzerland) · 2024Review
- Intratumoral Microbiota: Insights from Anatomical, Molecular, and Clinical Perspectives.Journal of personalized medicine · 2024Review
- Article
- Colorectal cancer microbiome programs DNA methylation of host cells by affecting methyl donor metabolism.Genome medicine · 2024Article
- Oxidative stress induced by Etoposide anti-cancer chemotherapy drives the emergence of tumor-associated bacteria resistance to fluoroquinolones.Journal of advanced research · 2024Article
- Exploring the gut microbiome's role in colorectal cancer: diagnostic and prognostic implications.Frontiers in immunology · 2024Review
- Interaction of human gut microbiota and local immune system in progression of colorectal adenoma (MIMICA-1): a protocol for a prospective, observational cohort study.Frontiers in oncology · 2024Article
- Influence of Microbiota on Tumor Immunotherapy.International journal of biological sciences · 2024Review
- Intratumoural microbiota: from theory to clinical application.Cell communication and signaling : CCS · 2023Review
- FFAR2 antagonizes TLR2- and TLR3-induced lung cancer progression via the inhibition of AMPK-TAK1 signaling axis for the activation of NF-κB.Cell & bioscience · 2023Article
- Integrative Metatranscriptomic Analysis Reveals Disease-specific Microbiome-host Interactions in Oral Squamous Cell Carcinoma.Cancer research communications · 2023Article
- Human microbiomes in cancer development and therapy.MedComm · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 4 countries.
Funding
Abstract
The study of the human microbiome in oncology is a growing and rapidly evolving field. In the past few years, there has been an exponential increase in the number of studies investigating associations of microbiome and cancer, from oncogenesis and cancer progression to resistance or sensitivity to specific anticancer therapies. The gut microbiome is now known to play a significant role in antitumor immune responses and in predicting the efficacy of immune-checkpoint inhibitors in cancer patients. Beyond the gut, the tumor-associated microbiome-microbe communities located either in the tumor or within its body compartment-seems to interact with the local microenvironment and the tumor immune contexture, ultimately impacting cancer progression and treatment outcome. However, pre-clinical research focusing on causality and mechanistic pathways as well as proof-of-concept studies are still needed to fully understand the potential clinical utility of microbiome in cancer patients. Moreover, there is a need for the standardization of methodology and the implementation of quality control across microbiome studies to allow for a better interpretation and greater comparability of the results reported between them. This review summarizes the accumulating evidence in the field and discusses the current and upcoming challenges of microbiome studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.